GlassScriptPhysician profile
Usama T Hussein
NPI 1194907527
$30,535.08
in general payments reported to CMS, 2019-2025
24 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $58.62 · 2021: $371 · 2022: $4,433 · 2023: $414 · 2024: $5,347 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $2,666 · Travel and Lodging: $600 · Education: $65.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,746.74 |
| Food and Beverage | $2,665.76 |
| Travel and Lodging | $599.68 |
| Education | $65.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $13,746.74 | 2025 | Defencath |
| Scpharmaceuticals INC. | $4,967.12 | 2024-2025 | |
| Travere Therapeutics, INC. | $4,710.00 | 2022-2025 | Filspari |
| Fresenius USA Marketing, INC. | $4,297.72 | 2019-2023 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $706.13 | 2019-2025 | Farxiga, Lokelma |
| Nxstage Medical, INC. | $588.90 | 2019-2025 | Nxstage System One, Liberty Select Cycler |
| Akebia Therapeutics INC | $250.80 | 2019-2024 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $207.61 | 2019-2025 | Jynarque |
| Amgen INC. | $178.14 | 2024-2025 | Tavneos, Procysbi |
| Outset Medical INC | $124.20 | 2023 | |
| Calliditas Therapeutics US INC. | $122.20 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $115.48 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $104.30 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $100.27 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $81.88 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $73.24 | 2022 | |
| Alexion Pharmaceuticals, INC. | $45.41 | 2022 | |
| Mallinckrodt Enterprises LLC | $27.27 | 2019 | |
| Apellis Pharmaceuticals, INC. | $24.01 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $21.43 | 2024 | |
| Baxter Healthcare | $15.79 | 2022 | |
| Glaxosmithkline, LLC. | $13.72 | 2025 | Shingrix |
| Horizon Therapeutics Plc | $12.72 | 2023 | Krystexxa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usama Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.